Cellular gene therapy (CGT) has become a new generation of breakthrough precision therapy, and related clinical transformation and commercialization are accelerating. According to Frost & Sullivan data, it is estimated that by 2025, the global CGT market will reach approximately US$30.54 billion, with a CAGR of 71% from 2020 to 2025. The overall popularity of the domestic CGT field is also increasing. In 2022, the scale of my country's CGT treatment market is expected to increase by 1025.21% year-on-year, and will continue to maintain a high growth trend of more than 100%.
On May 10, 2022, the National Development and Reform Commission released the "14th Five-Year Plan for the Development of Bioeconomy". This is my country's first five-year plan for bioeconomy, and it is also the first top-level design in the field of bioeconomy in my country. The plan clearly points out that the development of new technologies such as gene therapy, stem cell therapy, and immune cell therapy should be focused on, the collaboration between industry, university, research and application should be strengthened, and the transformation and clinical application of related technology products should be accelerated. It can be seen that the country attaches great importance to the field of cell gene therapy and is determined to develop it. Under the guidance of policies, related domestic industries are also stepping into a more standardized and rapid development track.
Favorable government policies, financial recognition and support, a large number of unmet clinical needs, and the establishment of CAR-T qualified hospitals will further promote the development of China's CGT market. However, the rapid development of the industry also means greater challenges in technology, production, and commercialization. The research and development of new cell gene therapy drugs, product commercialization roads, drug development for rare diseases, and related medical insurance programs are urgently concerned by many people in the industry. Questions need to be answered urgently.
In this context, the 3rd Asia Cell and Gene Therapy Innovation Summit of CGT Asia 2023 hosted by Taas Labs will be held in Shanghai from April 3rd to 4th, 2023 . At the same time, this conference specially set up the "CGT Awards CGT Industry Star" 2023 Asia-Pacific Cell and Gene Therapy Industry Star Awards Selection . There are more than 10 "CGT Industry Star" awards for the world. Online voting and expert review methods are used to provide strong support for the transformation of cell and gene therapy scientific research, promote the improvement of industry research and development capabilities, enhance brand influence, and promote industry-wide research and development progress.
Some exciting topics
Clinical value-oriented cell therapy research and development
Clinical application of mesenchymal stem cell therapy
3D cellular organization for therapy and drug evaluation
Progress of iPSC-induced pluripotent stem cells in the treatment of neurodegenerative diseases
How does cell therapy commercial insurance help products and patients?
Advances in gene therapy for transfusion-dependent β-thalassemia
How decentralized clinical trials support long-term follow-up of clinical research
Diverse Analytical Techniques to Assess Critical Quality Attributes of Viral Vector Processes
Identify rare diseases with precision medicine such as early screening and single-cell sequencing
A Patient-Centric Clinical Development Process for Rare Diseases
......
Part of the previous participating companies
Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Materia Medica, Ruijin Hospital, Shanghai Renji Hospital, Shanghai Tongji Hospital, Shanghai Tongren Hospital, Fudan University Biomedical Research Institute, Shanghai Jiaotong University School of Medicine, Wenzhou Medical University, BMS, Novartis (China) Biomedical Research Co., Ltd., BeiGene, Qilu Pharmaceutical, Innovent, Shanghai Pharmaceutical Group Biotherapy Technology Co., Ltd., Shanghai Inos Biotechnology Co., Ltd., Shanghai Cell Therapy Group, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Sunshine Pharmaceuticals, Zhejiang Terex Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Research Institute, WuXi AppTec, WuXi Shengji, Beijing Xinlida Pharmaceutical, Buchang Pharmaceutical, Fosun Kate, Henlius, WuXi Giant Nuo, Nanjing Legend, Junshi Bio, Reindeer Medical, Shanghai Danrui, Neophus, Si Microbiology, Nanjing Beiheng Biological, Xingdehan (Shanghai) Biomedical Co., Ltd., Xingyiang (Shanghai) Biotechnology, Beijing Kerui Biotechnology Co., Ltd., Best Onco Technology Co., Ltd. Biotechnology Co., Ltd., Yinuowei, Shanghai Huanma Biomedical Co., Ltd., Shanghai Bangyao Biotechnology Co., Ltd., Yuansong Biotechnology, Shanghai Rongrui Pharmaceutical Technology Co., Ltd., Stardust Biotechnology, Anuoling Road, Gracell Biotechnology (Shanghai) Co., Ltd., Chengdu Pioneer Drug Development Co., Ltd., Puxin Biotechnology, etc...
Some past speakers
On the left is Professor, Doctoral Supervisor/Chairman/Chief Scientist, Jimmy Ruisheng
Dr. Lin Jian, Senior Director of External Innovation R&D, Johnson & Johnson
Dr. Chang Yan, President, Enox-National Shanghai Center for Drug Safety Evaluation and Research
Dr. Shijiang Lu, President and Chief Executive Officer, Heppel Cell, Inc.
Dr. Yunxiang Zhu, Vice President of Global R&D, Cannes, Beihai
Dr. Yang Gao, Senior Vice President/Chief Strategy Officer, Bangyao Biotech
Dr. Jimin Gao, Professor, Wenzhou Medical University
Dr. Dai Hongjiu, Founder/Executive President, Nanjing Kaidi Medical
Dr. Yao Shuyuan, Chief Executive Officer, Annorling Road
Dr. Wang Min, Technical Director, Bosheng Gianke
Dr. Zhang Lei, Vice President of R&D, Xing Yiang
Dr. Ke Zhang, Chief Scientific Officer, Xing Hande
Dr. Yarong Liu, Founder and CEO, Grit Bio
Dr. Xingwang Xie, Chief Executive Officer, Kerui Biotech
Dr. Tianhong Xu, Founder/CEO, Best Biotech
Dr. Xinpo Jiang, Assistant Vice President/Reagent Product Development, GenScript
......
Highlights of CGT Asia 2022